Selank Neuropeptide Research Overview

Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro, MW 751.88 g/mol, CAS 129954-34-3) is a synthetic heptapeptide analogue of tuftsin extensively studied in neuronal cell models for GABA-A receptor modulation, BDNF pathway activity, and neurological signalling endpoint characterisation. This neuropeptide demonstrates distinct receptor binding profiles and enzymatic stability characteristics that make it valuable for investigating GABAergic neurotransmission mechanisms and neuroprotective signalling cascades in controlled laboratory environments.

Molecular Properties

| Property | Value |

|----------|--------|

| Molecular Formula | C₃₃H₅₇N₁₁O₉ |

| Molecular Weight | 751.88 g/mol |

| CAS Number | 129954-34-3 |

| Sequence | Thr-Lys-Pro-Arg-Pro-Gly-Pro |

The peptide structure incorporates multiple proline residues that confer enhanced proteolytic resistance compared to native tuftsin, enabling extended experimental timeframes in cell culture systems. The N-terminal threonine and C-terminal proline modifications contribute to improved membrane permeability characteristics essential for in vitro receptor binding studies.

GABA-A Receptor Research

GABA-A receptors are ligand-gated chloride ion channels expressed in SH-SY5Y neuroblastoma cells, primary cortical neurons, and hippocampal cell preparations commonly utilised for selank receptor pharmacology investigations. Research demonstrates that selank exhibits allosteric modulation properties at GABA-A receptor complexes, influencing chloride conductance through indirect mechanisms rather than direct orthosteric site binding.

Receptor Binding Kinetics

Competitive binding assays using radiolabelled GABA reveal selank's capacity to enhance GABA binding affinity at concentrations ranging from 10⁻⁸ to 10⁻⁶ M in membrane preparations. The peptide demonstrates positive allosteric modulation characteristics with EC₅₀ values of approximately 2.3 × 10⁻⁷ M for GABA potentiation in patch-clamp electrophysiology studies. Binding kinetics analysis indicates selank's interaction occurs through benzodiazepine-independent pathways, distinguishing its mechanism from classical GABA-A positive modulators.

Chloride Flux Measurements

Fluorescence-based chloride indicator assays in transfected HEK293 cells expressing α₁β₂γ₂ GABA-A receptor subunits demonstrate selank's ability to potentiate GABA-induced chloride influx. The peptide increases maximum chloride conductance by 40-60% while reducing the EC₅₀ for GABA activation from 8.2 μM to 3.1 μM, indicating enhanced receptor sensitivity to endogenous ligands.

BDNF Signalling Pathway Analysis

Brain-derived neurotrophic factor (BDNF) signalling represents a critical pathway for neuroplasticity mechanisms investigated through selank treatment in neuronal cell models. The peptide demonstrates capacity to modulate BDNF expression and downstream TrkB receptor activation in primary cortical cultures and differentiated neuroblastoma cell lines.

TrkB Receptor Phosphorylation

Western blot analysis reveals selank treatment at concentrations of 10⁻⁷ M induces TrkB receptor phosphorylation at Tyr706 and Tyr816 residues within 30-60 minutes of application. This phosphorylation pattern activates downstream PI3K/Akt and MAPK/ERK signalling cascades essential for neurotrophin-mediated cellular responses.

Gene Expression Modulation

Quantitative PCR studies in rat primary hippocampal cultures demonstrate selank's ability to upregulate BDNF mRNA expression by 2.5-fold compared to vehicle controls after 6-hour incubation periods. Additionally, the peptide increases expression of immediate early genes including c-Fos and Arc, indicating activation of transcriptional programs associated with synaptic plasticity mechanisms.

Enzymatic Stability and Metabolism

Proteolytic stability studies using serum and cerebrospinal fluid matrices reveal selank's enhanced resistance to peptidase degradation compared to native tuftsin. High-performance liquid chromatography analysis demonstrates a half-life of approximately 4.2 hours in 10% fetal bovine serum at 37°C, significantly extended compared to tuftsin's 15-minute degradation profile.

Metabolite Analysis

Mass spectrometry identification of selank metabolites in cell culture supernatants reveals primary cleavage sites between Pro-Arg and Arg-Pro bonds, generating fragments that retain partial biological activity in GABA-A receptor binding assays. The C-terminal tripeptide Pro-Gly-Pro demonstrates measurable receptor interaction with binding affinity approximately 100-fold lower than intact selank.

Research Summary

Selank represents a valuable research tool for investigating GABAergic neurotransmission and neurotrophin signalling pathways in controlled in vitro environments. The peptide's dual activity profile encompassing GABA-A receptor positive allosteric modulation and BDNF pathway activation provides unique opportunities for studying neuroprotective mechanisms at the cellular level. Enhanced proteolytic stability compared to native tuftsin enables extended experimental protocols, while distinct receptor binding kinetics offer insights into novel GABAergic modulation mechanisms. Continued research applications focus on elucidating structure-activity relationships and identifying specific receptor subtypes mediating selank's observed pharmacological effects in neuronal cell culture systems.

All content is intended for in vitro laboratory research purposes only. Not for human or animal consumption. Not intended to diagnose, treat, cure, or prevent any condition.